Berberine (BBR) is a novel natural hypolipidemic agent. This study investigates whether BBR, similar to statins, exerts pleiotropic effects on endothelial tissue factor (TF) expression. BBR enhanced tumor necrosis factor-alpha (TNF-alpha) and thrombin induced TF expression in human endothelial cells by 3.5-fold. These effects were paralleled by an enhanced TF surface activity. In contrast, expression of TF pathway inhibitor was impaired. BBR enhanced TNF-alpha induced TF mRNA expression; however, TF promoter activity was inhibited. Activation of ERK and p38 remained unaffected, while c-Jun terminal NH(2) kinase was inhibited. BBR reduced TF mRNA degradation rates, prolonging its half-life from 1.1 to 4.3 h. The HMG-CoA reductase inhibitor simvastatin impaired thrombin induced TF expression, and BBR blunted this inhibition. Simvastatin did not affect TNF-alpha induced TF expression, and BBR enhanced TF under these conditions. Administration of BBR (100 mg/kg/d) increased TF activity and impaired TFPI expression in carotid artery of ApoE(-/-) mice. BBR enhances TF via mRNA stabilization at clinically relevant concentrations. Clinical application of BBR, either as an alternative to or in combination with statins, should be considered with caution. 
Introduction
Arterial thrombosis is the critical event in acute coronary syndromes, peripheral ischemia, and stroke. Tissue factor (TF) plays an essential role in coagulation by binding factor VII, which activates factor X, finally leading to thrombin generation [1] . TF expression is detected in a variety of cell types within the atherosclerotic vessel wall and is induced by inflammatory mediators such as TNF-α, histamine, or lipopolysaccharide [2, 3, 4, 5] . Elevated levels of TF are indeed present in plaques from patients with unstable angina and enhance plaque thrombogenicity; further, an involvement of TF in drug-eluting stent thrombosis has been discussed as well [6, 7, 8] . Tissue factor pathway inhibitor (TFPI) acts as the direct endogenous inhibitor of the TF/FVIIa complex [9] .
Increasing evidence indicates that modulation of the physiological balance between TF and TFPI has an important impact on thrombus formation [10, 11] .
Berberine (BBR), an alkaloid isolated from the chinese herb huanglian (Coptis chinensis), has been extensively used in traditional Chinese medicine.
Recently, BBR was identified as a promising lipid-lowering drug, potently upregulating hepatic low-density lipoprotein (LDL) receptor expression. This effect occurred via LDL receptor mRNA stabilization rather than increased promoter activity and required extracellular signal regulated kinase (ERK) activation [12] . Further studies revealed that the BBR induced LDL receptor mRNA stabilization involved novel regulatory proteins located downstream of the ERK pathway and able to interact with sequences in the proximal section of the LDL receptor mRNA 3' untranslated region (UTR) [13] .
Since these observations suggest a therapeutic application of BBR, either as a monotherapy or in combination with statins, this study adressed the question whether BBR, similar to statins, exerts pleiotropic effects on endothelial TF expression.
Methods

Cell Culture
Human aortic endothelial cells (HAEC; Clonetics, Allschwil, Switzerland)
were cultured as described [3, 4] . Adhering cells were grown to confluence in 3 cm dishes and rendered quiescent in medium supplemented with 0,5% fetal bovine serum for 24 hours before stimulation with 5 ng/mL TNF-α (R&D Systems, Minneapolis, MN) or 1 U/ml thrombin (Sigma, St. Louis, MO). Cells were treated with BBR (Cayman Chemical, Ann Arbor, MI), simvastatin (Sigma), or both for 60 min prior to stimulation. Cytotoxicity was assessed with a colorimetric assay for detection of lactate dehydrogenase release (Roche, Basel, Switzerland).
Western Blot
Protein expression was determined by Western blot analysis as described [3, 4] . Antibodies against human TF and TFPI (both from American Diagnostica, Stamford, CT) were used at 1:2000 dilution. Antibodies against phosphorylated p38 MAP kinase (p38), p44/42 MAP kinase (extracellular signal regulated kinase [ERK]), and c-Jun NH2-terminal kinase (JNK; all from Cell Signaling, Danvers, MA) were used at 1:1000, 1:5000, and 1:1000 dilution, respectively. Antibodies against total p38, ERK, and JNK (all from Cell Signaling) were used at 1:2000, 1:5000, and 1:1000 dilution, respectively. All blots were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression (1:5000 dilution, Chemicon International, Temecula, CA).
TF activity at the surface of HAEC was analyzed using a colorimetric assay (American Diagnostica) [3, 4] . TF/FVIIa complex converted human factor X to factor Xa, which was measured by its ability to metabolize a chromogenic substrate. TF activity was measured against a standard curve performed with lipidated human TF to assure that measurements were taken in the linear range of detection.
Real Time PCR
Total RNA was extracted from HAEC using TRIzol Reagent (Invitrogen, Carlsbad, CA). Conversion of total cellular RNA to cDNA was carried out with Moloney murine leukemia virus reverse transcriptase and random hexamer primers (Amersham Biosciences, Piscataway, NJ) in a final volume of 33 µl using 4 µg of cDNA. Real time PCR was performed in an MX3000P PCR cycler (Stratagene, Amsterdam, The Netherlands) as described [7, 8] . All experiments were performed using the SYBR Green JumpStart kit (Sigma). Each reaction for 30 s, an annealing phase at 60˚C for 1 min, and an elongation phase at 72˚C for 1 min. A melting curve analysis was performed after amplification to verify the accuracy of the amplicon, and PCR products were analyzed on an ethidium bromide stained 1% agarose gel. In each real-time PCR run for TF and L28, a calibration curve was included that was generated from serial dilutions of purified amplicons.
TF Promoter Activity
The TF promoter (-227 bp to +121 bp) was inserted upstream of the was processed for real-time PCR analysis as described above. Values were then plotted on a logarithmic scale as a function of time, and the half-life was calculated using linear equation [15] .
In vitro RNA decay assay
A 297-bp PCR fragment from 3'-UTR of the human TF cDNA was subcloned into the BamHI and XhoI restriction sites of pBluescript II KS (+) (Stratagene).
This construct was linearized with KpnI and used as a template for generation of a 390-nt riboprobe labeled with 50 µCi [α- by gel-electrophoresis on 5% polyacrylamide gel containing 7M urea. Bands were visualized by autoradiography using a phosphoimager. 
In vivo study
Results
Berberine enhances TF protein expression and surface activity HAEC were stimulated with TNF-α (5 ng/ml) or thrombin (1 U/ml) for 5
hours. 1 hour pretreatment with BBR (1-30 µmol/l) enhanced TNF-α induced TF expression in a concentration-dependent manner with an EC50 value of 2 µmol/l (n=5; p<0.01; Figure 1A) ; the maximal effect occurred at 30 µmol/l and resulted in a 3.4-fold higher expression as compared to TNF-α alone. Similarly, BBR enhanced thrombin induced TF expression by 3.3-fold as compared to thrombin alone (n=5; p<0.05; Figure 1B ). BBR did not alter TF expression under basal conditions (n=10; p=NS; Figure 1A and B). The effect of BBR on TF expression was paralleled by an enhanced TF surface activity, which was 1.6 times higher than that by TNF-α alone (n=4; p<0.0005; Figure 1C ). BBR did not alter TF surface activity under basal conditions (n=4; p=NS; Figure 1C ).
BBR (1-30 µmol/l) inhibited TFPI expression of TNF-α stimulated HAEC by 45±15% as compared to TNF-α alone with an EC50 value of 5.7 µmol/l (n=4; p<0.05; Figure 1D ). Similarly, BBR impaired basal TFPI expression by 52±12% (n=4; p<0.005; Figure 1D ).
LDH release was not affected by any BBR concentration used (n=4;
p=NS; data not shown) indicating that BBR did not exert cytotoxic effects.
Berberine enhances TF mRNA level
Real-time PCR revealed that TNF-α induced TF mRNA expression within 2 hours of stimulation (n=5; p<0.0001; Figure 2A ). BBR (30 µmol/l) enhanced TNF-α induced TF mRNA expression by 1.6-fold as compared to TNF-α alone (n=5; p<0.05; Figure 2A ).
Berberine inhibits TF promoter activity
To assess whether the effect on TF mRNA was mediated by enhanced transcription, the impact of BBR on TF promoter activity was analyzed after transfection of HAEC with a plasmid expressing firefly luciferase under control of the human TF promoter (-221bp to +121bp). TNF-α enhanced TF promoter activity by 2.9-fold as compared to control conditions (n=4; p<0.0001; Figure   2B ). Treatment with BBR (30 µmol/l) impaired promoter activation (n=4;
p<0.001; Figure 2B ). BBR did not affect basal promoter activity (n=4; p=NS; Figure 2B ).
Berberine inhibits JNK phosphorylation
To determine whether inhibition of TF promoter activity was paralleled by inhibition of MAP kinases, phosphorylation of these mediators was assessed at different time points after TNF-α stimulation. TNF-α (5 ng/mL) transiently activated JNK, ERK, and p38; maximal activation was observed after 15 minutes and returned to basal levels within 60 minutes ( Figure 3A) . Treatment with BBR inhibited phosphorylation of JNK by 48±12% as compared to TNF-α alone (n=4; p<0.05; Figure 3B ), while phosphorylation of ERK and p38 was not significantly reduced (n=4; p=NS; Figure 3B ). Total expression of JNK, ERK, and p38 remained unaffected at all time points examined ( Figure 3A) . p=NS; Figure 4B ).
Berberine abrogates the inhibitory action of statins on TF expression
Statins exert pleiotropic anti-thrombotic effects through inhibition of TF expression in different cell types including endothelial cells [16, 17, 18] . Since statins and BBR exhibit additive lipid-lowering effects, the impact of such a combination on endothelial TF protein expression was examined. Simvastatin (1 µmol/l) inhibited thrombin induced TF expression by 40±14% as compared to thrombin alone (n=5; p<0.05; Figure 5A ), while such an effect was not observed in TNF-α stimulated endothelial cells (n=4; p=NS for TNF-α + simvastatin vs TNF-α alone; Figure 5B ). BBR antagonized the inhibitory effect of simvastatin on thrombin induced TF expression (n=5; p<0.05 for simvastatin + BBR vs simvastatin alone; p=NS for simvastatin + BBR vs BBR alone; Figure 5A ). In both thrombin and TNF-α stimulated HAEC, treatment with simvastatin had no effect on the enhanced TF expression occurring in the presence of BBR (n=4; p=NS; Figure 5B ).
BBR enhances TF and inhibits TFPI in vivo
The effect of berberine on expression of TF and TFPI was assessed in ApoE -/-mice. Animals were treated for 10 days with berberine (100 mg/kg/d).
The left common carotid artery was harvested for analysis of TF activity and TFPI expression. TF activity was enhanced by nearly 2-fold in the berberine treated group (n=7; p<0.05; Figure 6A ). This increase in TF activity was paralleled by a 43.5% decrease in TFPI expression as compared to control (n=7; p<0.05; Figure 6B ).
This study demonstrates that BBR, at clinically relevant concentrations stimulating hepatic LDL receptor expression [12] , enhances TNF-α and thrombin induced endothelial TF expression via stabilization of TF mRNA.
Moreover, BBR inhibits endothelial TFPI expression, and abrogates the inhibitory effects of statins on endothelial TF. Similar effects on TF and TFPI are observed in ApoE -/-mice treated with BBR. These observations suggest that application of BBR as a lipid-lowering medication, either alone or in combination with a statin, may favor the development of thrombosis, in particular in the inflammatory environment of atherosclerotic lesions [19] .
As endothelial cells are situated at the luminal surface of vessels and thereby exposed to circulating FVII, modulation of TF expression at the endothelial surface can have major consequences for thrombus formation. BBR enhanced TNF-α and thrombin induced TF expression, suggesting that it promotes thrombus formation under both inflammatory and prothrombotic conditions. Since TF is inhibited by TFPI, the balance of these factors is essential for vascular homeostasis [9, 10, 20] . In addition to enhancing TF, BBR impaired basal as well as TNF-α induced endothelial TFPI expression, which represents an additional prothrombotic potential. These effects of BBR on TF and TFPI may be particularly relevant in acute coronary syndromes, which are usually triggered by vascular inflammation leading to thrombus formation.
The BBR concentrations applied in vitro (1 to 30 µmol/l) are comparable to those used in another study [12] , where concentrations ranged from 0.5 to 15 µg/ml corresponding to 1.3 to 40 µmol/l. The pharmacokinetics of berberine in humans are barely understood and still need to be characterized. However, a study performed in patients with congestive heart failure reported that oral administration of 1.2 g BBR per day led to plasma concentrations of 190±0.08 ng/ml (0.5±0.03 µmol/l) [21] . For the in vivo animal studies performed by others as well as for our own in vivo experiments, BBR was administrated orally at a dose of 50 and 100 mg/kg/d corresponding to an oral intake of 3 and 6 g BBR per day, respectively, for an adult weighing 60 kg [12] ; hence, BBR intake was higher than in the study performed in humans, suggesting that BBR plasma concentrations may well reach values of 2 µmol/l under these conditions. The berberine mediated effects on endothelial TF were statistically significant at concentrations as low as 1 µmol/l, and consistent with a biologically relevant concentration range, the in vivo effects of BBR on TF and TFPI were similar to those observed in human cells.
The MAP kinases JNK, ERK, and p38 are critically involved in mediating transcriptional regulation of TF expression in response to both TNF-α and thrombin [1] . Although BBR enhanced TF mRNA levels, it inhibited activation of JNK without affecting that of ERK and p38, and, in line with this observation, impaired TF promoter activation. These data indicate that BBR upregulates TF mRNA by a post-transcriptional mechanism able to counteract the impaired TF promoter activation. Analysis of TF mRNA decay rates indeed confirmed that BBR prolonged the half life of TF mRNA from 64 to 260 minutes, highlighting the crucial role of mRNA stability in the regulation of TF expression. A similar effect on the half life of TF mRNA was observed with dexamethasone in human monocytes [5, 22] . The importance of mRNA stability in mediating TF expression, however, varies depending on the stimulus involved; indeed, LPS induces TF mainly by enhancing mRNA stability rather than increasing the rate of transcription, while the opposite effect accounts for the action of PMA [23] .
Hence, it is conceivable that the mechanism of action of BBR on endothelial TF expression differs depending on the stimulus activating the endothelium.
In mammalian cells, AU sequences regrouped to AUUUA pentamers in so-called AU-rich elements (ARE) located in the 3' untranslated region of mRNA are known to modulate mRNA decay [12, 24, 25] . ARE have been described in the 3'-UTR of human TF mRNA and are involved in TF mRNA turnover [22, 26] . 
